“We have never had more data, and never had less of it read.”
Allan started paying attention in 2018, watching the science expand faster than the law around it and wondering whether the trials, the statutes and the money would follow the shape cannabis had already traced. Almost none of it was written down anywhere a reader could check a claim against. The database dates to 2019, started while the industry around it was still forming, and after several starts and stops The Psilocybin Record launched in 2026.
The pieces start in the register. Some are a question the data answers outright; more are a matter of reading what sits scattered across the filings and setting it down in one place. Allan reports what the documents show and leaves the arguing to other people. Every figure arrives with the denominator it came from, and every claim names the statute, the registration or the release it rests on. When the answer is that nobody has published the number, that is the piece.
Topics covered
- Prescribing and access routes
- Clinical trials and their sponsors
- Scheduling decisions
- Legislation
Analysis
- Oregon dropped its proposed psilocybin fee increase, and its own forecast for that path leaves the programme $3.9 million short by June 2027.Oregon’s August forecast for its psilocybin programme assumes no General Fund money, and all three of its scenarios, with or without the increase, end short. None of the authority’s budget documents says the programme will stop.
- Health Canada says it has approved 354 Special Access requests for psilocybin since 2022.These are practitioners’ requests: one can cover several patients, and one patient can need several. Patients cannot apply directly, and a yes does not oblige a manufacturer to supply.
- How many Australians have been prescribed psilocybin?Through June 2025, prescribers reported 47 new patients, none in the first six months. Some may be counted twice, and the regulator has no public dashboard for them, as it does for medicinal cannabis.
- Trump’s psychedelics order named a Right to Try route for seriously ill patients, and none exists.Executive Order 14401 set no deadline for the route it asked the FDA and the DEA to build for eligible patients, and nothing creating it has been published since April.
- Who makes the psilocybin in a clinical trial?In roughly 8% of registered psilocybin trials, the name on the drug isn’t the sponsor’s. No index built on sponsors can show that, and ours is one of them.
- Italy’s psilocybin trials run on Canadian capsules made from mushrooms Italy bans by name.In practice, the only way to psilocybin therapy in Italy is a place in one of two registered trials for treatment-resistant depression, where some participants receive placebo capsules. No patient has been publicly reported treated outside them.
- Governments reported 19.22 kilograms of pure psilocybin made in 2024, excluding mushrooms.Making it lawfully takes four permissions. Two US states publish who holds them, and Canada’s list goes to those seeking access through its Special Access Program or for scientific research, a 2023 filing says.
- Backers of Colorado’s 2022 psilocybin measure reported $5.8 million in contributions, and opponents reported $51,000.Those are the totals filed by two supporting committees and one opposing committee. Massachusetts voters rejected Question 4 in 2024, and its money had a different shape.
- Of eighteen publishers sizing the psychedelic drugs market, one states its method on its free page.The one is Market Research Future, which gives psilocybin no dollar value of its own and builds its estimate partly from prescriptions for esketamine, a different drug.
- Filament Health Corp. supplies the study drug in 16 psilocybin trials and sponsors one.Usona Institute supplies 11 and sponsors four, on the 5 September 2026 read. A sponsor index cannot see either supplier, and no registry behind these trials published what any of them cost.
- Eight states’ drug laws already describe a crystalline form of psilocybin that the FDA has not approved.Eleven states have enacted a measure deciding what their drug schedules do if the FDA approves a psilocybin medicine. No such medicine is approved, and none of them changed the law for generic psilocybin.
- Of about 330 registered psilocybin trials, 120 name depression and 52 name no patient condition at all.Each registration is a statement of intent at filing and says nothing about whether psilocybin helps anyone. Newer trials name a wider spread of conditions, and depression grew alongside them.
Analysis argues from the register and is labelled as analysis. It never writes back into an entry.